SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/65277"
 

Search: onr:"swepub:oai:gup.ub.gu.se/65277" > Rosuvastatin in old...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005422naa a2200949 4500
001oai:gup.ub.gu.se/65277
003SwePub
008240528s2007 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/652772 URI
0247 a https://doi.org/10.1056/NEJMoa07062012 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Kjekshus, John4 aut
2451 0a Rosuvastatin in older patients with systolic heart failure.
264 1c 2007
520 a BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
653 a Aged
653 a Cardiovascular Diseases
653 a epidemiology
653 a mortality
653 a Female
653 a Fluorobenzenes
653 a adverse effects
653 a therapeutic use
653 a Follow-Up Studies
653 a Heart Failure
653 a drug therapy
653 a etiology
653 a Hospitalization
653 a statistics & numerical data
653 a Humans
653 a Hydroxymethylglutaryl-CoA Reductase Inhibitors
653 a adverse effects
653 a therapeutic use
653 a Male
653 a Middle Aged
653 a Myocardial Ischemia
653 a complications
653 a Proportional Hazards Models
653 a Pyrimidines
653 a adverse effects
653 a therapeutic use
653 a Single-Blind Method
653 a Sulfonamides
653 a adverse effects
653 a therapeutic use
653 a Systole
653 a Treatment Outcome
7001 a Apetrei, Eduard4 aut
7001 a Barrios, Vivencio4 aut
7001 a Böhm, Michael4 aut
7001 a Cleland, John G F4 aut
7001 a Cornel, Jan H4 aut
7001 a Dunselman, Peter4 aut
7001 a Fonseca, Cândida4 aut
7001 a Goudev, Assen4 aut
7001 a Grande, Peer4 aut
7001 a Gullestad, Lars4 aut
7001 a Hjalmarson, Åke,d 1937u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xhjala
7001 a Hradec, Jaromir4 aut
7001 a Jánosi, András4 aut
7001 a Kamenský, Gabriel4 aut
7001 a Komajda, Michel4 aut
7001 a Korewicki, Jerzy4 aut
7001 a Kuusi, Timo4 aut
7001 a Mach, François4 aut
7001 a Mareev, Vyacheslav4 aut
7001 a McMurray, John J V4 aut
7001 a Ranjith, Naresh4 aut
7001 a Schaufelberger, Maria,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xscmar
7001 a Vanhaecke, Johan4 aut
7001 a van Veldhuisen, Dirk J4 aut
7001 a Waagstein, Finn,d 1938u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xwaafi
7001 a Wedel, Hans4 aut
7001 a Wikstrand, John,d 1938u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xwikjo
7102 a Göteborgs universitetb Wallenberglaboratoriet4 org
7730 t The New England journal of medicineg 357:22, s. 2248-61q 357:22<2248-61x 1533-4406
8564 8u https://gup.ub.gu.se/publication/65277
8564 8u https://doi.org/10.1056/NEJMoa0706201

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view